诱导化疗和KMT2A重新排列的AML中的分子MRD影响结果
Jad Othman1, Nicola Potter2, Sylvie D Freeman3
1Kings College London, London, United Kingdom.
Blood
|August 6, 2025
概括
在KMT2A重组的急性髓性白血病 (AML) 患者中,FLAG-Ida化疗显著降低了复发率. 早期分子最小残留疾病 (MRD) 评估是患者结果的强有力的预测指标.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 重组KMT2A的急性髓性白血病 (AML) 是一个独特的亚型,具有特定的治疗考虑因素.
- 优化化疗方案和早期预后标记对于改善AML患者存活率至关重要.
研究的目的:
- 为了评估FLAG-Ida化疗方案的疗效,与KMT2A重组AML的其他方案相比.
- 为了确定分子最小残留疾病 (MRD) 评估在这个患者队列的预后价值.
主要方法:
- 从两个连续的随机试验 (AML17和AML19) 中对217名KMT2A重组AML患者的分析.
- 用FLAG-Ida治疗的患者和其他化疗方案之间的复发率的比较.
- 在第二周期后评估分子MRD作为复发和死亡的预后因素.
主要成果:
- 与其他化疗方案相比,随机分配给FLAG-Ida的患者的复发率明显较低.
- 第二周期后的分子MRD评估是复发和死亡的强有力的预测因素.
- 该研究包括来自ISRCTN55675535 (AML17) 和ISRCTN78449203 (AML19) 的数据.
结论:
- 通过减少复发率,FLAG-Ida疗法与KMT2A重新安排的AML的改善结果有关.
- 早期的分子MRD监测对于风险分层和指导KMT2A重组AML的治疗决策至关重要.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


